



Prism Medico And Pharmacy Limited

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 12/02/2021

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai-400 001

To,
Listing Department,
**Metropolitan Stock Exchange of India Ltd.
(MSE)**
Vibgyor Towers, 4th floor,
Plot No C 62, G - Block,
Opp. Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai-400 098, India.
ISIN : INE730E01016

Scrip Code: 512217

Dear Sir / Madam,

Sub.: Approval of Un-Audited Financial Results for the quarter ended 31st December, 2020

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 12/02/2021 at the Registered Office of the company have considered and approved the Un-Audited Financial Statements for the quarter ended 31st December, 2020. In this regards, we are enclosing herewith:

1. Un- Audited Financial Results for the quarter ended 31st December, 2020.
2. Auditors' Limited Review Report on Un- Audited Financial Results for the quarter ended 31st December, 2020.

You are requested to kindly take the same on record.

Thanking You,


Yours Truly,

For **PRISM MEDICO AND PHARMACY LIMITED**

Sudhanshu Srivastava

Director

DIN: 08242441



PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2020 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Period Ended (Unaudited)	Year Ended (Audited)
	31.12.2020	30.09.2020	31.12.2019		
1 INCOME FROM OPERATIONS				31.12.2020	31.03.2020
A Net Sales/ Income From Operations	606.72	637.77	950.56	1244.49	2689.01
B Other Operating Income	0.00	0.00	0.00	0.00	
TOTAL INCOME FROM OPERATIONS (NET)	606.72	637.77	950.56	1244.49	2689.01
2 EXPENSES:					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchase of Stock-In-Trade	570.20	597.98	1452.42	1168.18	2569.70
Change In Inventories	-0.32	0.00	-503.78	-0.32	91.38
Employee Benefit Expenses	0.42	0.42	9.17	0.98	21.90
Depreciation	0.31	0.31	1.73	0.92	1.76
Other expenses	0.85	1.35	1.73	6.82	11.05
TOTAL EXPENSES	571.46	600.06	959.54	1176.58	2695.79
3 PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)	35.27	37.71	-8.98	67.91	-6.78
4 Other Income	0.00	0.00	0.00	0.00	0.00
5 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)	35.27	37.71	-8.98	67.91	-6.78
6 Finance Cost	0.00	0.00	0.00	0.00	0.02
7 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)	35.27	37.71	-8.98	67.91	-6.80
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00
9 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)	35.27	37.71	-8.98	67.91	-6.80
10 TAX EXPENSE:					
(1) Current Tax	9.17	9.80	0.00	17.66	0.00
(2) Deferred Tax	0.0089	0.0089	0.00	0.02	1.78
(3) MAT Credit	0.00	0.00	0.00	0.00	0.00
11 NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)	26.09	27.90	-8.98	50.24	-5.02

12	Extraordinary Items (Net of Tax ` Expense _____ Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)	26.09	27.90	-8.98	50.24	14.70	-5.02			
14	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00			
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00			
16	NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	26.09	27.90	-8.98	50.24	14.70	-5.02			
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34	606.34			
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	748.30	722.21	748.96	748.30	680.84	699.25			
19	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):									
	(1) BASIC	0.04	0.05	-0.01	0.08	0.02	-0.01			
	(2) DILUTED	0.04	0.05	-0.01	0.08	0.02	-0.01			
19	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):									
	(1) BASIC	0.04	0.05	-0.01	0.08	0.02	-0.01			
	(2) DILUTED	0.04	0.05	-0.01	0.08	0.02	-0.01			

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12TH FEBRUARY 2021

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.

3. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.

FOR & ON BEHALF OF THE BOARD
PRISM MEDICOTRA MEDICO and PHARMACY LTD.



Sudhanshu Sivastay
Director
DIN: 08242441

Place : Mohali

Date: 12/02/2021

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST DECEMBER, 2020

PARTICULARS		31.12.2020	31.03.2020
I. ASSETS			
(1)	Non - Current Assets		
	(a) Property, Plant and Equipment	585,381	677,381
	b) Financial Assets		
	(1) Non-Current Investments	19,380,000	19,380,000
	b) Deferred Tax Asset	132,590	136,134
(2)	Current Assets		
	(a) Inventories	508,579	475,729
	b) Financial Assets		
	(1) Cash & Cash Equivalent	1,077,305	1,117,555
	(2) Short Term Loans and advances	10,051,337	10,356,338
	(3) Trade Receivables	190,200,904	183,361,367
	(c) Other Current Asset	336,741	336,741
TOTAL Rs.		222,272,836.97	215,841,244.60
II EQUITY AND LIABILITIES			
(1)	Equity		
	(a) Equity Share Capital	60,634,280	60,634,280
	(b) Other Equity	74,829,720	69,925,246
(2)	Current Liabilities		
	a) Financial Liabilities		
	(1) Trade Payables	84,508,428	84,480,968
	(b) Other Current Liabilities	2,300,409	800,750
TOTAL Rs.		222,272,836.97	215,841,244.13

